Edgewise Therapeutics, Inc.
EWTX
$29.69
-$0.81-2.66%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 25.58% | 27.46% | 35.34% | 37.78% | 35.88% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.51% | 22.98% | 28.17% | 37.79% | 38.89% |
| Operating Income | -20.51% | -22.98% | -28.17% | -37.79% | -38.89% |
| Income Before Tax | -25.40% | -26.51% | -30.05% | -38.01% | -33.60% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -25.40% | -26.51% | -30.05% | -38.01% | -33.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.40% | -26.51% | -30.05% | -38.01% | -33.60% |
| EBIT | -20.51% | -22.98% | -28.17% | -37.79% | -38.89% |
| EBITDA | -20.77% | -23.18% | -28.37% | -38.13% | -38.97% |
| EPS Basic | -12.96% | -5.73% | -1.46% | -0.86% | 7.98% |
| Normalized Basic EPS | -12.94% | -5.73% | -1.47% | -0.87% | 7.96% |
| EPS Diluted | -12.96% | -5.73% | -1.46% | -0.86% | 7.98% |
| Normalized Diluted EPS | -12.94% | -5.73% | -1.47% | -0.87% | 7.96% |
| Average Basic Shares Outstanding | 11.35% | 17.85% | 25.63% | 35.10% | 45.02% |
| Average Diluted Shares Outstanding | 11.35% | 17.85% | 25.63% | 35.10% | 45.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |